VEENENDAAL, The Netherlands, April 24 /PRNewswire/ --
- Strong Product Offerings and Leadership in Brachytherapy Contribute to All-Time High
Nucletron, a global leader in radiation oncology, today announced strong financial results in 2008 with net sales of EUR112.4 million (US $165 million). EBITDA in 2008 ended at an all time high (in constant currencies) of EUR17 million with a strong fourth quarter contributing significantly to the year-end success. Despite challenging global economic conditions, Nucletron surpassed projections in 2008 due in large part to a renewed focus on brachytherapy treatment and an expanding product offering in external beam treatment planning software solutions.
Among the several advancements announced in 2008 was the introduction on Oncentra(R) Brachy, a new comprehensive volume-based treatment planning solution that optimizes cancer treatment planning with brachytherapy. Additionally, Oncentra(R) RT Viewer received clearance in 2008. Oncentra RT Viewer enables clinicians to review radiotherapy plans generated with a wide variety of DICOM-compliant treatment planning systems in a Windows (PC) environment.
“In the second half of 2008, we improved our focus on innovation and marketing efforts, while strengthening our management team. Given our many upcoming product releases in the months to come, we are on track to achieve our 2009 goals as planned,” said Jos Lamers, chief executive officer of Nucletron.
About Nucletron
Nucletron is a global leader in Radiation Oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams - reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians. For more information, visit http://www.nucletron.com.
CONTACT: Media Contact: Danielle Davis, +1-443-834-6725,
ddavis@rosecomm.com
